Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients

The trial showed 15.7% average weight loss over 68 weeks, below expectations and earlier trial results, causing a significant drop in stock value.

Novo Nordisk's phase 3 REDEFINE 2 trial results showed CagriSema led to 15.7% weight loss for patients with obesity and type 2 diabetes over 68 weeks, compared to 3.1% for placebo.
The results fall short of the company’s earlier REDEFINE 1 trial, where patients without diabetes achieved a 22.7% weight loss over the same period.
Investors were disappointed as expectations for CagriSema were higher, given its combination of semaglutide (used in Wegovy and Ozempic) and cagrilintide, a dual hormone agonist.
Shares of Novo Nordisk dropped by over 7% following the announcement, marking a significant hit to the company’s stock value.
Despite the underwhelming results, Novo Nordisk plans to seek regulatory approval for CagriSema in early 2026, with two additional trials still underway.